Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28149607 | 0.87 | MALT1 (0.58) | TP53LMNAPOLBMALT1MAPT | |
| SCHEMBL31694392 | 0.84 | EPHX2 (0.69) | EPHX2LMNAMAPTMTNR1AKMT2A | |
| SCHEMBL173219 | 0.84 | EPHX2 (0.69) | EPHX2LMNAMAPTMTNR1AKMT2A | |
| SCHEMBL19003837 | 0.83 | ESR1 (0.47) | EPHX2TP53LMNAPOLBMALT1 | |
| SCHEMBL13213549 | 0.83 | ESR1 (0.47) | EPHX2TP53LMNAPOLBMALT1 | |
| SCHEMBL27904456 | 0.82 | MTNR1A (0.63) | TP53LMNAPOLBMALT1MAPT | |
| SCHEMBL27904454 | 0.82 | MTNR1A (0.63) | TP53LMNAPOLBMALT1MAPT | |
| Tert-Butyl Formate SCHEMBL28149613 | 0.82 | TP53 (0.49) | EPHX2TP53LMNAPOLBMALT1 | |
| SCHEMBL17478422 | 0.82 | EPHX2 (0.45) | EPHX2TP53LMNAPOLBMALT1 | |
| SCHEMBL17478347 | 0.82 | MALT1 (0.46) | EPHX2TP53LMNAPOLBMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10787428-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, RXRA | EPHX2 417/4885TP53 2938/4885LMNA 1763/4885 |
| US-10787428-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | EPHX2 545/4885TP53 2960/4885LMNA 2043/4885 |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | EPHX2 475/4885TP53 3092/4885LMNA 1785/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | EPHX2 545/4885TP53 2960/4885LMNA 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.